Brokerages have maintained a robust growth outlook for drugmaker Sun Pharma following the release of its April-June earnings on August 3. Though the company's net profit declined 2 percent on year to Rs 2,022.5 crore in the first quarter of the current financial year, the fall was mostly on account of an exceptional loss worth Rs 322.87 crore.